MARKET

NBRV

NBRV

Nabriva
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.839
+0.049
+2.73%
Opening 11:05 03/08 EST
OPEN
1.800
PREV CLOSE
1.790
HIGH
1.850
LOW
1.750
VOLUME
530.94K
TURNOVER
--
52 WEEK HIGH
14.70
52 WEEK LOW
1.520
MARKET CAP
65.07M
P/E (TTM)
-0.2422
1D
5D
1M
3M
1Y
5Y
Antibiotic resistance market is anticipated to grow at considerable CAGR over 5.5% over the forecast period | ARC
pune, India, Mon, 08 Mar 2021 01:01:08 / Comserve Inc. / -- The global antibiotic resistance market is anticipated to grow at considerable CAGR over 5.5%...
Comserve · 10h ago
The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings
Biotech stocks continued to move southward in the week ended March 5, as the broader market extended its sell-off. Though light on news, the week did witness earnings releases from smaller biopharma companies, coronavirus vaccine program updates, mixed FDA...
Benzinga · 2d ago
The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 4)
Benzinga · 3d ago
Blueprint Medicines (BPMC) Gets EMA Validation for Ayvakyt in SM
Zacks.com · 4d ago
Nabriva Therapeutics to Report 2020 Financial Results and Recent Corporate Highlights on March 11, 2021
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its fourth quarter and full year 2020...
GlobeNewswire · 4d ago
Kodiak Sciences (KOD) Misses on Q4 Earnings, KSI-301 in Focus
Zacks.com · 6d ago
Axsome's (AXSM) Q4 Earnings Miss Estimates, Pipeline in Focus
Zacks.com · 6d ago
The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 1)
Benzinga · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NBRV. Analyze the recent business situations of Nabriva through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NBRV stock price target is 9.00 with a high estimate of 9.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 85
Institutional Holdings: 36.00M
% Owned: 101.75%
Shares Outstanding: 35.39M
TypeInstitutionsShares
Increased
11
763.26K
New
19
493.38K
Decreased
8
2.55M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
+1.10%
Key Executives
Chairman - Supervisory/Independent Director
Daniel Burgess
President/Chief Operating Officer
Steven Gelone
Chief Executive Officer/Director
Theodore Schroeder
Chief Financial Officer/IR Contact Officer
Gary Sender
General Counsel/Secretary
Robert Crotty
Other
Francesco Lavino
Other
Jennifer Schranz
Director
Colin Broom
Independent Director/Supervisory Board
Carrie Bourdow
Independent Director/Supervisory Board
Charles Rowland
Independent Director/Supervisory Board
George Talbot
Independent Director/Supervisory Board
Stephen Webster
No Data
About NBRV
Nabriva Therapeutics plc is a biopharmaceutical company engaged in the commercialization and development of anti-infective agents to treat serious infections. The Company’s product XENLETA (lefamulin), is a semi-synthetic pleuromutilin antibiotic for systematic administration in humans. It inhibits the synthesis of bacterial protein, which is required for bacteria to grow by binding with high affinity, high specificity and at molecular targets that are different than other antibiotic classes. The Company is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.

Webull offers kinds of Nabriva Therapeutics PLC - ADR stock information, including NASDAQ:NBRV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBRV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NBRV stock methods without spending real money on the virtual paper trading platform.